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Escherichia coli sequence type 131 (ST131), an emergent multidrug-resistant extraintestinal pathogen, has
spread epidemically among humans and was recently isolated from companion animals. To assess for human-
companion animal commonality among ST131 isolates, 214 fluoroquinolone-resistant extraintestinal E. coli
isolates (205 from humans, 9 from companion animals) from diagnostic laboratories in Australia, provisionally
identified as ST131 by PCR, selectively underwent PCR-based O typing and blaCTX-M-15 detection. A subset
then underwent multilocus sequence typing (MLST), pulsed-field gel electrophoresis (PFGE) analysis, ex-
tended virulence genotyping, antimicrobial susceptibility testing, and fluoroquinolone resistance genotyping.
All isolates were O25b positive, except for two O16 isolates and one O157 isolate, which (along with six
O25b-positive isolates) were confirmed by MLST to be ST131. Only 12% of isolates (25 human, 1 canine)
exhibited blaCTX-M-15. PFGE analysis of 20 randomly selected human and all 9 companion animal isolates
showed multiple instances of >94% profile similarity across host species; 12 isolates (6 human, 6 companion
animal) represented pulsotype 968, the most prevalent ST131 pulsotype in North America (representing 23%
of a large ST131 reference collection). Virulence gene and antimicrobial resistance profiles differed minimally,
without host species specificity. The analyzed ST131 isolates also exhibited a conserved, host species-indepen-
dent pattern of chromosomal fluoroquinolone resistance mutations. However, eight (89%) companion animal
isolates, versus two (10%) human isolates, possessed the plasmid-borne qnrB gene (P < 0.001). This extensive
across-species strain commonality, plus the similarities between Australian and non-Australian ST131 iso-
lates, suggest that ST131 isolates are exchanged between humans and companion animals both within Aus-
tralia and intercontinentally.
Escherichia coli is a major cause of extraintestinal infection
in both humans and companion animals (2, 42). Such isolates
exhibit resistance to multiple antimicrobial classes, including
fluoroquinolones, with increasing frequency worldwide, thus
posing a significant treatment challenge to physicians and
veterinarians alike.
The virulent E. coli clonal group sequence type 131 (ST131),
which is associated with fluoroquinolone resistance and be-
longs to phylogenetic group B2, has shown recent and rapid
global dissemination. This clonal group is an emerging human
pathogen in many parts of the world, including continental
Europe (3, 33), the United Kingdom (28), Turkey (52), Korea
(30), Canada (36, 38), and the United States (18, 19). Its
association with blaCTX-M-15, which encodes the CTX-M-15
extended-spectrum -lactamase (ESBL), has also influenced
the recent pandemic spread of extended-spectrum cephalospo-
rin resistance (3, 4, 18, 28, 29, 34, 44).
Recently, ST131 has also been isolated from sporadic cases
of extraintestinal infection in companion animals (13, 22, 24,
40). This supports previous evidence that extraintestinal patho-
genic E. coli (ExPEC) from humans and companion animals,
particularly strains belonging to group B2, share similar viru-
lence genotypes and phylogenetic origins (25, 31).
In a previous study by our group, fluoroquinolone-resistant
(FQr) E. coli from extraintestinal infections in humans and
companion animals were collected over a 2-year period in
Eastern Australia (39). Clonal group ST131 accounted for 35%
of human isolates and 7% of companion animal isolates (39).
Here, we sought to further characterize these ST131 isolates
for a broad range of molecular and phenotypic traits, both to
assess for clonal commonality across host species within Aus-
tralia and to compare these isolates to a broader international
collection.
MATERIALS AND METHODS
Bacterial isolates. As reported elsewhere (39), a collection of 707 FQr clinical
extraintestinal E. coli isolates from humans (n  582) and companion animals
(n  125) from Eastern Australia (October 2007 to October 2008) underwent
PCR-based determination of major E. coli phylogenetic group (A, B1, B2, and
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D) (5). The 263 group B2 isolates (i.e., 250 human and 13 companion animal [12
canine, 1 feline] isolates) were screened for ST131 status by PCR-based detec-
tion of ST131-specific single-nucleotide polymorphisms (SNPs) in mdh and gyrB
(23). The 214 (205 human, 9 companion animal) thus-identified ST131 isolates
(39), which due to the timing and geography of the cases suggested no link
among the animal cases, or between animal versus human cases, underwent
further characterization here.
Initial characterization of isolates. The 214 putative ST131 isolates were
screened by PCR for the ST131-associated O25b rfb variant (7) and blaCTX-M-15
(6). Isolates that were not type O25b (n  3) underwent PCR for 12 additional
sepsis-associated rfb variants (O1, O2, O4, O6, O7, O12, O15, O16, O18, O25a,
O75, and O157) (6). For confirmation of the ST131 status, nine presumptive
ST131 isolates, of which six (three human and three canine ST131 isolates)
exhibited the O25b rfb variant and three (all human) exhibited unique non-O25b
rfb variants, underwent confirmatory multilocus sequence typing (MLST) accord-
ing to the Achtman system (http://mlst.ucc.ie/mlst/dbs/Ecoli), using DNA se-
quence analysis of seven housekeeping genes (50). Approximately 10% of human
ST131 isolates (20/205; 9.8%) were randomly selected for comparison with all
nine companion animal ST131 isolates (eight canine, one feline) according to
multiple additional characteristics, determined as described below.
PFGE. Genomic DNA of the 29 selected ST131 isolates underwent XbaI
pulsed-field gel electrophoresis (PFGE) according to a standardized protocol
(41). Dice coefficient-based similarity dendrograms were constructed within
BioNumerics (Bio-Rad, Applied Maths) according to the unweighted pair group
method with arithmetic means. Isolates were considered to represent the same
pulsotype if they exhibited 94% profile similarity, which corresponds with a
3-band overall difference (45). PFGE profiles were compared both within this
collection and to an unpublished PFGE reference library comprising 533 E. coli
ST131 isolates, obtained from around the world, but mainly the United States
and Canada (23; J. R. Johnson, unpublished data [see also Table 2]).
Virulence genotyping. The 29 selected ST131 isolates were screened by PCR
for 53 ExPEC-associated virulence genes and variants (17, 20, 26, 35, 47). Vir-
ulence scores were the numbers of virulence genes detected for each isolate. The
virulence genotype similarity between two isolates was calculated as the number
of shared virulence genes divided by the combined total number of virulence
genes.
Susceptibility testing. All isolates underwent disk diffusion susceptibility test-
ing to enrofloxacin (9), with fluoroquinolone resistance defined as nonsuscepti-
bility. The 29 selected ST131 isolates underwent disk diffusion susceptibility
testing to 18 additional antimicrobial agents (amoxicillin-clavulanic acid, ampi-
cillin, aztreonam, cefepime, cefoxitin, ceftazidime, cephalothin, chlorampheni-
col, ciprofloxacin, gentamicin, imipenem, nitrofurantoin, piperacillin, streptomy-
cin, piperacillin-tazobactam, tetracycline, and trimethoprim-sulfamethoxazole)
and determination of broth microdilution MICs for four fluoroquinolones (en-
rofloxacin, ciprofloxacin, moxifloxacin, and pradofloxacin, a new veterinary fluo-
roquinolone) (48). The methods and interpretive criteria used were as specified
by the Clinical and Laboratory Standards Institute (8, 9), except for pradofloxa-
cin (resistance breakpoint, 2 g/ml) (14).
Detection of chromosomal fluoroquinolone resistance mutations. The quino-
lone resistance-determining region (QRDR) of gyrA, encoding subunit A of
DNA gyrase (primary fluoroquinolone target), was screened for resistance mu-
tations by a rapid pyrosequencing-based method using the primers gyrA-5-211
(5-GGTGACGTAATCGGTAAATATCA-3) and gyrA-3-329-biotin (5-CC
GAAGTTACCCTGACCATCTA-3). The cycling conditions were as follows: 5
min of denaturation at 94°C; 35 cycles of 94°C for 30s, 61°C for 40 s, and 72°C
for 45 s; and then 5 min of elongation at 72°C. The resulting 118-bp PCR
fragment was analyzed by using the sequencing primer gyrA-5-222-EcoMPC-
seq (5-CGGTAAATACCATCCCCA-3) on a PSQ MA96 Pyrosequencer ac-
cording to the manufacturer’s instructions (Biotage, Uppsala, Sweden). The
corresponding region of parC, encoding subunit A of topoisomerase IV (second-
ary fluoroquinolone target), was amplified and sequenced as described previously
(16). SNPs were defined relative to the wild-type E. coli strain (WT).
Detection of plasmid-mediated resistance genes. The plasmid-mediated quin-
olone resistance genes qnrA, qnrB, qnrS, and qepA, which encode three target-
protecting proteins and an efflux pump, respectively, were screened for by mul-
tiplexing existing and novel single PCRs, with a second PCR screen used to
identify isolates containing aac(6)-Ib. The primers and product sizes are listed in
Table 1; controls were as described previously (11). PCR conditions were: 5 min
of denaturation at 95°C; 30 cycles of 95°C for 30 s, 57°C for 30 s, and 72°C for
50 s; and then 10 min of elongation at 72°C. All aac(6)-Ib-positive isolates
underwent digestion of the PCR product with FokI and NdeI (New England
Biolabs, Ipswich, MA) to identify the aac(6)-Ib-cr variant, which encodes a
bifunctional aminoglycoside-fluoroquinolone modifying enzyme (27).
Efflux pump activity testing. Two methods were used to detect efflux pump
activity, including MIC testing in the presence of an efflux pump inhibitor and an
organic solvent tolerance test. For efflux pump inhibitor testing, broth microdi-
lution susceptibility to the four studied fluoroquinolones was determined in
duplicate in the presence or absence of 64 g of L-phenylalanyl-arginyl--naph-
thylamide (PAN; Sigma P 4157)/ml (8, 9). For organic solvent tolerance, over-
night cultures (ca. 109 CFU/ml) of each isolate underwent four 10-fold serial
dilutions. Approximately 1-l portions of the last three dilutions (ca. 105, 106,
and 107 CFU/ml) were spotted onto the surface of an LB agar plate and allowed
to dry. Then, 15 ml of an organic solvent (hexane, cyclohexane, and hexane-
cyclohexane combinations of 3:1, 1:1, and 1:3) was overlaid on the plate to a
depth of 2 to 3 mm. The plates were sealed with petroleum jelly and laboratory
film, followed by incubation at 30°C for 48 h. Growth was then recorded for each
spot as confluent, visible, or absent. Controls included the E. coli strain pairs
AG100-AG102 and WT-MIII (16, 49). Organic solvent tolerance was scored as
no growth inhibition in the presence of 100% hexane (), 3:1 hexane-cyclo-
hexane (), 1:1 hexane-cyclohexane (), 1:3 hexane-cyclohexane
(), or 100% cyclohexane (). Growth inhibition was defined as a
reduction in the initial inoculum of the bacterial concentration by at least two
10-fold serial dilutions in the presence of each respective organic solvent.
Statistical analysis. A Fisher exact test (two-tailed) was used to compare
proportions. The Mann-Whitney U test (also two-tailed) was used to compare
continuous variables. To simplify the virulence gene and antimicrobial suscepti-
bility data for comparisons of human versus companion animal isolates, principle
coordinates analysis (PCoA) was used. PCoA is a multidimensional scaling
method that captures within the first two PCoA axes most of the total variance
contained in a multivariable, multispecimen data set.
TABLE 1. Primers used to detect plasmid-mediated fluoroquinolone resistance genes
Target gene(s) Primer Sequence (5–3)a Product size (bp) Source or reference
aac(6)-lb and aac(6)-lb-cr aac6 for ATGACTGAGCATGACCTTGC 519 This study
aac6 rev TTAGGCATCACTGCGTGTTC This study
qnrA qnrA for TCAGCAAGAGGATTTCTCA 626 31
qnrA rev GGCAGCACTATGACTCCCA 31
qnrB qnrB for GGCGAAAAAATTTACAGAAA 525 This study
qnrB rev TCYGAATTGGTCARATCRCA This study
qnrS qnrS for TGCAAGTTTCCAACAATGCC 367 This study
qnrS rev GATCTAAACCGTCGAGTTCG This study
qepA qepA for CTTCCTGCCCGAGTATCGTG 217 51
qepA rev GCAGGTCCAGCAGCGGGTAG 51
a IUPAC code: R  A or G; Y  C or T.
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RESULTS
O types, confirmatory MLST, and screening for blaCTX-M-15.
The O25b rfb variant was detected in 211 (98.6%) of the 214
presumptive ST131 isolates, including 202 (98.5%) of the 205
human and all 9 (100%) companion animal isolates. Of the
three non-O25b isolates, two were O16, and one was O157 by
O-type PCR. However, seven-locus MLST confirmed the
ST131 status of these three non-O25b isolates and all six (three
human, three companion animal) randomly selected O25b-
positive isolates. Of the 214 total isolates, only 12% (25 human,
1 canine) exhibited blaCTX-M-15.
PFGE analysis. To assess within-clonal group and cross-
species genomic commonality at a more highly resolved level,
the 29 selected ST131 isolates underwent XbaI PFGE analysis
(Table 2 and see also the supplemental material). Although
none of the selected isolates were indistinguishable from one
another, 19 (66%) exhibited 94% PFGE profile similarity to
another isolate in the group and so could be considered clonal
(i.e., from a multiple-isolate pulsotype). Three such multiple-
isolate pulsotypes were identified (Table 2). First, 12 (6 human,
5 canine, and 1 feline) isolates (41% of 29) exhibited profiles
corresponding with reference pulsotype 968, the most common
pulsotype (prevalence, 23%) in an unpublished PFGE profile
reference library that comprises 533 E. coli ST131 isolates,
mainly from the United States (23) (Table 2). An additional
four human isolates matched pulsotype 800 (prevalence in refer-
ence library, 14%), and three other human isolates matched pul-
sotype 812 (prevalence in reference library, 5%, including one
animal isolate). Six additional isolates (four human, two canine)
exhibited profiles that, although representing unique pulsotypes
within the present study, matched other reference library pulso-
types (prevalence in library, 3% each). Notably, for these two
canine isolates, the same-pulsotype isolates within the reference
library included human isolates (Table 2). The remaining four
isolates (three human and one canine) each represented a novel
pulsotype, i.e., were 94% similar to any study isolate or refer-
ence library isolate (Table 2). Thus, eight of nine companion
animal isolates represented human-isolate-matching pulsotypes
(Table 2), whereas the sole remaining canine isolate represented
a novel, single-isolate pulsotype.
Virulence genotypes. Of the 53 virulence genes sought, 24
(45%) were detected among the 29 selected ST131 isolates.
Aggregate virulence scores ranged from 7 to 19 (median, 12);
the virulence genotype similarity ranged from 68 to 100%. Six
different virulence genes were present in 90% of the 29
isolates: fimH (type I fimbriae, 100%), fyuA (yersiniabactin
receptor, 100%), usp (uropathogenic-specific protein, 100%),
ompT (outer membrane protease, 97%) malX (pathogenicity
island marker, 93%), and iutA (aerobactin receptor, 93%). In
addition, present in 75% of isolates were sat (secreted auto-
TABLE 2. PFGE analysis of 20 human and 9 companion animal E. coli ST131 isolates compared to a large reference librarya
Pulsotype(s)b
Present study (n  29 ST131 isolates) Reference library (n  533 ST131 isolates)c
No. (%) of
isolates
No. of human
isolates
(n  20)
No. of animal
isolates
(n  9)
Rank order
in library
No. (%)
of isolates
No. of human
isolates
Distribution No. of animal
isolatesCountry No.
968 12 (41) 6 5 dogs, 1 cat 1 121 (23) 110 US 94 11d
Canada 14
India 1
Portugal 1
800 4 (14) 4 0 2 77 (14) 77 US 55 0
Canada 20
India 2
812 3 (10) 3 0 3 29 (5) 28 US 24 1d
Canada 1
Spain 2
Portugal 1
905 1 (3) 0 1 dog 4 18 (3) 18 US 14 0
Canada 4
807 1 (3) 1 0 6 6 (1) 6 US 4 0
Canada 2
838 1 (3) 1 0 15 3 (0.6) 3 US 3 0
920 1 (3) 0 1 dog 25 1 (0.2) 1 US 1 0
915 1 (3) 1 0 38 1 (0.2) 1 France 1 0
975 1 (3) 1 0 39 1 (0.2) 1 US 1 0
796, 976, 1110,
and 1153
1 (3) each 3 1 doge NA* NA* NA* NA* NA
a The reference library currently comprises 533 ST131 isolates from diverse locales, hosts, and clinical contexts (J. R. Johnson, unpublished data).
b Pulsotypes are defined at the 94% Dice coefficient similarity level and are labeled sequentially as they are encountered.
c US, United States. NA*, not applicable (these pulsotypes are represented in the reference library only by isolates from the present study); NA, not applicable (no
animal isolates in pulsotype).
d The listed reference collection animal isolates were from the United States.
e The dog isolate was pulsotype 1153.
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transporter toxin, 86%), the F10 papA allele (P fimbria struc-
tural subunit variant, 79%), iha (adhesin-siderophore receptor,
79%), and traT (serum resistance associated, 76%). Further-
more, present in 50% of isolates were kpsMII (group 2 cap-
sule, 66%) and kfiC (K5 group 2 capsule variant, 52%). Human
and companion animal isolates did not differ appreciably for
the prevalence of any individual virulence gene or, according
to a PCoA, for aggregate virulence profile (see the supplemen-
tal material).
Susceptibility testing. Disk diffusion susceptibility testing to
19 antimicrobials showed that the 29 selected ST131 isolates
were resistant to a median of 8 (range, 3 to 13) agents each (see
the supplemental material). All were resistant to ampicillin,
and over half, regardless of the host species, were resistant to
piperacillin (90%), cephalothin (79%), streptomycin (72%),
trimethoprim-sulfamethoxazole (66%), and tetracycline
(59%). Human and companion animal isolates did not differ
significantly for resistance prevalence for any of the antimicro-
bials tested. Fluoroquinolone MICs ranged from 0.5 to 128
g/ml for enrofloxacin (median, 64 g/ml) and ciprofloxacin
(median, 32 g/ml), 1 to 32 g/ml for moxifloxacin (median, 16
g/ml), and 0.25 to 8 g/ml for pradofloxacin (median, 4 g/
ml) (see the supplemental material). Human and companion
animal isolates did not differ significantly for aggregate resis-
tance profiles according to PCoA or fluoroquinolone MICs
(see the supplemental material).
Detection of fluoroquinolone resistance-associated muta-
tions in chromosomal genes. All but 1 of the 29 selected ST131
isolates had the same combination of four SNPs in the QRDRs
of gyrA (i.e., TCG to TTG [S83L] and GAC to AAC [D87N])
and parC (i.e., AGT to ATT [S80I] and an atypical GAA to
GTA [E84V]) (see the supplemental material). The sole ex-
ception (QUC012) had been classified as FQr based on its
intermediate enrofloxacin susceptibility by disk diffusion, and
yet it (alone among the 29 isolates) displayed full fluoroquin-
olone susceptibility by broth microdilution (ciprofloxacin MIC,
0.5 g/ml) and, of the above mutations, exhibited only gyrA
S83L. Notably, the 29 ST131 isolates also all exhibited a silent
parC SNP, i.e., CAG instead of CAA (codon 91).
Detection of plasmid-mediated resistance genes. Among the
29 selected ST131 isolates, only 2 of 20 human isolates, versus 8
of 9 companion animal isolates, contained qnrB (P  0.001). No
isolate contained qnrA, qnrS, or qepA. Three human isolates but
no companion animal isolates contained aac(6)-1b-cr (P 0.05);
one of these human isolates also contained qnrB. The presence of
qnrB and/or aac(6)-1b-cr showed no correlation with fluoroquin-
olone MIC values (see the supplemental material).
Efflux pump activity. For all 29 selected ST131 isolates, the
MICs of enrofloxacin, moxifloxacin, and pradofloxacin exhib-
ited 4-fold reductions in the presence of efflux pump inhib-
itor PAN, suggesting active efflux pumps. However, only two
isolates (one human, one companion animal) exhibited organic
solvent tolerance, and this was only low level (i.e., “”) (see
the supplemental material).
DISCUSSION
This study sought to characterize human and companion
animal FQr E. coli ST131 isolates obtained from cases of ex-
traintestinal infection in Australia and to identify the degree of
commonality across host species strains. We found that most
companion animal ST131 strains showed a high degree of
relatedness to Australian (and North American) human ST131
strains on the basis of PFGE profile, virulence gene content,
fluoroquinolone resistance-associated chromosomal muta-
tions, and antibiogram analyses, evidence suggesting interspe-
cies transmission, in whichever direction. Australian ST131
isolates are of particular interest since fluoroquinolones are an
important antimicrobial class that has been used in humans
and pets in Australia for over 20 years (1) but was never
authorized for use in Australian livestock (10).
E. coli ST131 isolates from around the world have been
reported to closely resemble one another genotypically, sug-
gesting rapid, global dissemination. This has been attributed to
multiple factors, including direct human-to-human transmis-
sion (12), international travel (37), environmental dissemina-
tion (43), fecal carriage in livestock (and spread via raw meats)
(46), and carriage by domestic (13, 24) or wild (15) animals.
Our findings support the concept that companion animals
probably participate in the dissemination of ST131 strains of
human relevance.
Interestingly, our findings show that most of the studied
companion animal and human ST131 isolates belong to pulso-
types present within an international ST131 strain collection,
including a predominantly CTX-M-15-negative pulsotype of
high prevalence in North America (pulsotype 968). Pulsotype
968 strains have been isolated previously from a dog (urine)
and cohabiting cats (feces) in the United States (24). Notably,
all but one of the present companion animal isolates repre-
sented a pulsotype that includes human isolates, in this collec-
tion and/or the reference library. This cross-species common-
ality suggests that either (i) ST131 strains are able to cross the
human-companion animal species barrier or (ii) humans and
companion animals can acquire ST131 strains from a common
external source.
The common-source hypothesis is supported by the recent
identification of FQr ST131 in poultry meat (32, 46), poultry
feces, and extraintestinal infections in chickens (32). These
poultry isolates were similar by PFGE profile and virulence
gene content to human ST131 isolates from the same locality
(32, 46). However, this cannot be extrapolated to the present
study, since Australia has a permanent ban on the importation
of fresh poultry products, and FQr E. coli have not been de-
tected in Australian poultry (1).
Only 26 (only 12%) of our 214 study isolates (25 human, 1
canine) tested positive for blaCTX-M-15, and the 4 CTX-M-15-
positive isolates among the 29 isolates that underwent PFGE
analysis represented three distinct pulsotypes. Horizontal ac-
quisition of a CTX-M-15-encoding plasmid appears to have
occurred relatively recently within ST131, subsequent to the
development of fluoroquinolone resistance in ancestral ST131
clones (18). The low prevalence of blaCTX-M-15 among our
study isolates may reflect either the high prevalence of the
typically blaCTX-M-15-negative pulsotype 968 (18) or a generally
low prevalence of CTX-M-15 among Australian FQr ST131
isolates regardless of clonal background (44).
Strains of E. coli from phylogenetic group B2 have been
shown to possess enhanced molecularly inferred virulence ca-
pacity compared to those from other E. coli phylogenetic
groups but are generally more antimicrobial susceptible (21).
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Although lacking certain traditional B2-associated virulence
traits, ST131 strains still possess numerous virulence genes (23,
34) in addition to multidrug resistance. Our isolates displayed
similarly extensive virulence gene profiles regardless of host
species, suggesting substantial virulence potential for humans
and companion animals alike irrespective of immediate source.
Since ST131 isolates have a known association with fluoro-
quinolone resistance, we also compared resistance mechanisms
between human and companion animal isolates. Animal and
human isolates possessed identical chromosomal resistance
mutations and similar efflux phenotypes. The identical (and
ST131-specific) pattern of gyrA and parC mutations supports
the concept of clonal spread. Sequence analysis of the QRDR
of parC revealed two distinctive nonsynonymous SNPs and one
synonymous SNP, indicative of a specific parC genotype in the
ST131 lineage. One of the nonsynonymous parC mutations
(GAA to GTA) affecting codon 84 (E84V) is unusual for E.
coli but was previously reported in 14 FQr isolates in the
United States (18), evidence of its disseminated and lineage-
specific nature.
In contrast to the high degree of commonality between hu-
man and companion animal ST131 isolates from Australia
according to other assessed traits, the companion animal iso-
lates exhibited a significantly higher prevalence of the plasmid-
mediated qnrB gene. Since qnr genes have been previously
demonstrated in multidrug-resistant E. coli isolates from com-
panion animals in Australia belonging to phylogenetic groups
A and D, companion animal FQr E. coli isolates may have a
generally higher prevalence of these genes compared to human
isolates (14). Given the (mobile) plasmidic nature of qnrB, this
minor point of host-specific differentiation may reflect recent
acquisition of qnrB after these strains entered the canine pop-
ulation. Interestingly, qnrB was not associated with increased
fluoroquinolone MICs, evidence that among these isolates
fluoroquinolone resistance is due primarily to chromosomal
mutations.
Addition of the efflux pump inhibitor PAN yielded a 4-
fold MIC reduction for enrofloxacin, moxifloxacin, and prado-
floxacin in all ST131 isolates, perhaps reflecting intrinsic activ-
ity of MDR efflux pumps. However, since only two isolates
showed even low-level tolerance to organic solvents (and to
hexane only), the overall importance of efflux pumps as a
resistance mechanism in ST131 cannot be demonstrated. No-
tably, of the four fluoroquinolones tested, pradofloxacin, an
expanded-spectrum fluoroquinolone developed solely for the
companion animal market, showed the lowest fluoroquinolone
MICs (2 to 8 g/ml).
In conclusion, we found that fluoroquinolone-resistant E.
coli ST131 isolates from humans and companion animals in
eastern Australia possess extensive similarities according to
genomic backbone, virulence gene content, resistance profile,
and chromosomal fluoroquinolone resistance mechanisms.
Pets likely play a small but potentially significant role in ST131
transmission dynamics. ST131’s high molecularly inferred vir-
ulence potential, its broad host range, and its multidrug resis-
tance phenotype make it important for both humans and com-
panion animals. Our findings suggest a need for ongoing
surveillance of both human and veterinary antimicrobial-resis-
tant pathogens in order to detect both the spread of existing
clonal groups and the emergence of novel lineages.
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